Recombinant factor IX - Baxalta
Alternative Names: BAX 326; Coagulation Factor IX (Recombinant) - Baxalta; Nonacog gamma - Baxalta; rFIX; RixubisLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Baxter International
- Developer Baxter International; Takeda
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia B
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-III for Haemophilia B (Treatment-experienced) in Taiwan (IV)
- 15 Sep 2020 No development reported - Phase-III for Haemophilia B (Treatment-experienced) in Taiwan (IV)
- 17 Sep 2019 Launched for Haemophilia B in New Zealand (IV) before September 2020